This study is looking into whether people with a genetic change linked to alpha-1 antitrypsin deficiency (a condition that can affect your lungs and liver) also have other genetic differences that might make them more prone to infections. Researchers will give participants the 20-valent pneumococcal conjugate vaccine (PCV20) and then measure their immune response after 4 weeks. They want to see if there's a difference in how well the vaccine works in people who have had no COPD (Chronic Obstructive Pulmonary Disease) flare-ups versus those who have had two or more in the past year. You might be able to join if you are an adult with a specific genetic change for alpha-1 antitrypsin deficiency and haven't recently received certain pneumonia vaccines. The study aims to enroll 30 participants, but its current recruitment status is unclear.

Study design

This is an interventional study, meaning participants will receive a specific treatment (the PCV20 vaccine). It plans to enroll 30 participants.

What's involved

Participants will receive the PCV20 vaccine. Your antibody response will be measured 4 weeks after the vaccine is given.

Compensation

Not stated in the trial record.

Follow-up

Your immune response will be measured at 4 weeks from a baseline measurement.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.